Newly released products will drive revenue growth, but will they benefit shareholders?
News & Analysis: Boston Scientific
High demand for a single product can't sustain an industry.
The pandemic has slowed sales for the two medical device companies. Which stock is ready to rise when medical procedures return?
BSX earnings call for the period ending March 31, 2020.
But a sharp decline in medical procedures caused a drop in first-quarter profits.
The company's Coventor will retail for under $1,000.
The coronavirus outbreak meant the postponement of medical procedures, weighing on Boston Scientific’s revenue.
The company did not offer updated guidance for its full-year fiscal 2020 results.
Revenue prospects after the coronavirus outbreak make these companies a good buy today.
Fewer elective surgery procedures in China may weigh on Boston Scientific’s first-quarter earnings.